Victoria's chief health officer, Dr Caroline McElnay, issued a public health alert on 19 June 2026 about acute liver injury in people who had injected unapproved peptide products sold under labels including Retatrutide, Reta, R-10 and R-20.
The alert described six cases in the Australian state since January 2026 and said similar cases were suspected in other jurisdictions.
Patients turned up with fatigue, yellowing of the skin or eyes, abdominal pain, dark urine and easy bruising, and their bloodwork showed elevated liver enzymes, sometimes with raised bilirubin and impaired clotting. Symptoms appeared within weeks of exposure.
Authorities continued investigating a possible bad batch
The alert's working theory is that a contaminant in the products, rather than the labelled ingredient by itself, may be driving the toxicity.
By August 24, 2026, ABC News in Australia reported a seventh Victorian patient hospitalised with severe liver injury after a second dose, plus at least one further case handled by health services in Canberra.
Dr Marie Sinclair, a liver transplant specialist who treated affected patients, told ABC she had commissioned laboratory testing of vials but that contamination remained a hypothesis while results were pending.
Professor Robyn Langham, the Therapeutic Goods Administration's chief medical adviser, told the broadcaster the cluster looked geographically contained and consistent with a bad batch, and stressed that what is being sold on the gray market is not the same material used in clinical trials.
An earlier ABC report in June described a tested vial that contained roughly twice the strength printed on its label.
The TGA said, as reported by ABC, that more than 94,500 unapproved peptide products had been destroyed this year in work with the Australian Border Force.
The TGA issued a broader warning in July about unapproved peptides, including products labeled retatrutide. It said these products have not been evaluated for safety, quality, or effectiveness. Their ingredients, strength, sterility, and manufacturing conditions may be unknown.
The illicit market extends beyond Australia
In the United States, retatrutide is an investigational Eli Lilly compound still in Phase 3 testing. No regulator anywhere has approved it for human use.
On August 12, 2026, Lilly filed six federal lawsuits in Texas against businesses it accused of selling the compound illegally.
BioPharma Dive reported that the company has referred more than 200 people and entities to regulators and flagged more than 14,000 websites, advertisements, social posts and product listings across more than 100 countries.
Axios reported the same week that demand for the unapproved drug has grown into an active illicit market.
People with symptoms need prompt medical care
The practical lesson is about the supply chain, not the molecule.
When an injectable peptide is bought outside a licensed pharmacy, nobody has verified its identity, its strength, its sterility or what else is in the vial.
A product at double the labelled strength is dangerous even if the labelled ingredient is exactly what it claims to be, and the June alert makes clear that additional substances in these vials are a live suspicion.
If you have injected an unapproved peptide and develop yellow skin or eyes, dark urine, unusual bruising, persistent nausea or right-sided abdominal pain, seek care promptly, tell the clinician exactly what you took, and bring the product or a photograph of it.
In Australia, the Poisons Information Centre can be reached on 13 11 26. Clinicians in the alert are asked to consider peptide use when they see unexplained abnormal liver tests.
Adverse events and suspected unlawful products can be reported to the TGA through the links in its notice.
Trial-grade retatrutide has not been implicated
This is not evidence that retatrutide itself causes liver failure. The compound being studied under regulatory supervision has not been implicated in these cases, and investigators suspect contamination or incorrect dosing in gray-market material.
Testing was not complete when these reports were published, so the cause remains unconfirmed. The numbers are also small, concentrated in one state, and come without any denominator for how many people used these products without harm, so no rate of risk can be calculated from them.
Nor does this say anything about approved GLP-1 medicines dispensed by a licensed pharmacy, which are a different situation entirely.
Educational information only. This brief is not medical advice. Do not start, stop, or change treatment based on it.
Reporting note
OTN reviewed the linked sources and documents listed above. The article identifies estimates, projections, unresolved questions, and the limits of the evidence.
Editorial standards, corrections, and commerce disclosure · About BariatricPal · About the brief author · Contact BariatricPal